Inhibitors of BRAF dimers using an allosteric site

Inhibitors of BRAF dimers using an allosteric site

FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which limits their clinical efficacy in tumors expressing BRAFV600E mutant monomers. Here the authors identify FDA-approved Ponatinib as an effective inhibitor of BRAF monomers and dimers and designed PHI1, an inhibitor with a unique mode of ac...

Full description

Bibliographic Details
Main Authors: Xiomaris M. Cotto-Rios, Bogos Agianian, Nadege Gitego, Emmanouil Zacharioudakis, Orsi Giricz, Yang Wu, Yiyu Zou, Amit Verma, Poulikos I. Poulikakos, Evripidis Gavathiotis
Format: Article
Language:English
Published: Nature Publishing Group 2020-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-18123-2

Internet

https://doi.org/10.1038/s41467-020-18123-2

Similar Items